Eculizumab (Soliris; Alexion), a C5 inhibitor preventing cleavage into C5a and C5b, is widely considered the first-line therapy for high-risk TA-TMA.
Hayden Mitteer, PharmD Candidate
Advertisement
Articles by Hayden Mitteer, PharmD Candidate
Advertisement
Latest Updated Articles
Eculizumab and Other Therapies for the Treatment of High-Risk Transplant-Associated Thrombotic MicroangiopathyPublished: October 3rd 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Exercise Program Manages Persistent Symptoms Post-COVID-19 Infection
2
The Controversial 340B Rebate Pilot Program Is Moving Forward
3
FDA Approves IsoPSA Blood Test to Detect Prostate Cancer
4
Cardiometabolic and Psychiatric Risks Converge as Heart–Mind Connection Sharpens
5
